
The Vision Council report highlights providers’ expectations and the perceived impact of economic factors including tariffs, inflation, staffing and hiring, and technological integration including telehealth and artificial intelligence.

The Vision Council report highlights providers’ expectations and the perceived impact of economic factors including tariffs, inflation, staffing and hiring, and technological integration including telehealth and artificial intelligence.

Under the Vevye Access for All program, patients with a Klarity-C prescription can switch to Vevye for $59 per bottle.

Cecelia Koetting, OD, FAAO, DipABO, and Madeline Yung, MD, detailed the prevalence of the conditions, diagnostic tools, and treatment options.


Good safety profile and “meaningful improvement” in vision in patient with Leber congenital amaurosis.

Dr Rachelle Lin highlights the urgent need for early intervention in childhood myopia, discusses associated retinal and systemic risks, and emphasizes the long-term impact of axial length control in reducing serious ocular complications.

A Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025, was set by the organization.

Rachelle Lin, OD, MS, FAAO, and Quan Đông Nguyễn, MD, MSc, presented available treatment options and what is coming down the pipeline for retinal conditions.

The expansion will allow the company to double the number of intraocular lenses manufactured every year to 4 million.

Brimochol PF’s combination of brimonidine and carbachol produces a “pinhole effect,” which is intended to improve depth of focus and sharpen near and distant impact.

The lens has been introduced to select practices across the US, with broad commercial availability planned for in May.

The novel corrective eye drop can be prescribed through pharmacy partners BlinkRx or Medvantx.

Nordic Pharma plans to announce commercialization details in the near future for the dry eye disease treatment.

Methylphenidate is a central nervous system stimulant that is used to treat ADHD, a very common diagnosis in children in the US.

Healing properties can accelerate and improve outcomes for patients.

Catch up on the top stories in optometry during the week of March 31-April 4.

The new lenses are designed for young presbyopes, ranging in age from their late 30s to mid-40s, who may be either existing spectacle wearers or non-wearers.

Management strategies for patients with ocular syphilis primarily involve antibiotic treatment achieved using high-dose intravenous or intramuscular penicillin.

Pantheon Vision’s bioengineered corneal implant aims to tackle issues with the success rate of human donated tissue.

A pivotal phase 3 clinical trial found that SYD-101 met its 3-year primary end point for slowing pediatric myopia progression.

Melissa Tawa, OD, FAAO, provides insights to take glaucoma management from reactive to proactive in presentations given at CRU 2025 in Napa, California.

The company stated that the FDA noted at least one additional adequate and well controlled study to demonstrate a positive effect on the treatment of ocular symptoms of dry eye should be conducted.

Understanding the precise formulation of pharmacologic agents for refractive correction for presbyopia.

Rachelle Lin, OD, MS, FAAO, details her presentation on inherited retinal diseases at CRU 2025.

The May 4 event, themed around Star Wars, will feature the latest innovations, foster open discussions, and provide a collaborative environment for networking and learning, with sessions covering IOLs, oculoplastics, glaucoma, retina therapy, and refractive surgical options.

From Stargardt to macular telangiectasia type 2, Kensington Hatcher, OD, FAAO, FORS; and Srinivas Kondapalli, MD, detail other conditions that share similarities to AMD.

Researchers assessed the costs to patients and caregivers in Germany, Bulgaria and the US.

Cecelia Koetting, OD, FAAO, DipABO, and Madeline Yung, MD, discussed emerging treatment and patient care options for those with presbyopia during CRU 2025.

Jennifer Li, MD, details a talk she gave alongside Melissa Barnett, OD, FAAO, FSLS, FBCLA, at CRU 2025 in Napa, California.

Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.